<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836182</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 757456-CS5</org_study_id>
    <secondary_id>2020-005878-10</secondary_id>
    <nct_id>NCT04836182</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>ASTRAAS-HF</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously Over 12 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC)&#xD;
      injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week&#xD;
      13) and to evaluate the effect of IONIS-AGT-LRx weekly SC injection on plasma AGT&#xD;
      concentration and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) levels at&#xD;
      each scheduled visit in chronic heart failure participants with reduced ejection fraction&#xD;
      (HFrEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 72&#xD;
      participants. Participants will be randomized in a 2:1 ratio to either IONIS-AGT-LRX or&#xD;
      matching placebo and receive a once-weekly SC treatment. The length of participation in the&#xD;
      study will be approximately 29 weeks, which includes an up to 4-week screening period, a&#xD;
      12-week treatment period, and a 13-week post-treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Plasma AGT Concentration From Baseline to Study Day 85</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Level of Plasma AGT</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma AGT From Baseline to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma AGT From Baseline to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Level of NT-proBNP</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP From Baseline to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in NT-proBNP to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline to Day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-AGT-LRX by subcutaneous injection once-weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo by subcutaneous injection once-weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-AGT-LRx</intervention_name>
    <description>Multiple doses of IONIS-AGT-LRx will be administered by SC injection.</description>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <other_name>ISIS 757456</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IONIS-AGT-LRx-matching placebo will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females must be non-pregnant and non-lactating and of non-childbearing potential.&#xD;
&#xD;
          2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with&#xD;
             a woman of child-bearing potential (WOCBP), she must be willing to use a highly&#xD;
             effective contraceptive method&#xD;
&#xD;
          3. Screening NT-proBNP ≥ 600 picograms per milliliter (pg/mL) and less than (&lt;) 8500&#xD;
             pg/mL&#xD;
&#xD;
          4. Established diagnosis of heart failure (HF) with reduced systolic function for at&#xD;
             least 6 months prior to the screening visit (left ventricular ejection fraction,&#xD;
             [LVEF] ≤ 40%&#xD;
&#xD;
          5. New York Heart Association class I-III&#xD;
&#xD;
        Participants should receive background standard of care for HFrEF. Therapy should have been&#xD;
        individually optimized and stable for ≥ 4 weeks before randomization and include:&#xD;
&#xD;
          1. An angiotensin-converting-enzyme inhibitor (ACEi), or angiotensin II receptor blockers&#xD;
             (ARBs) or sacubitril/valsartan (mandatory)&#xD;
&#xD;
          2. A beta-blocker (unless contraindicated or not tolerated)&#xD;
&#xD;
          3. A mineralocorticoid receptor antagonist (MRA, unless contraindicated or not tolerated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any cause of chronic HF other than ischemic cardiomyopathy and dilated cardiomyopathy&#xD;
&#xD;
          2. Acute decompensated HF requiring intravenous (IV) diuretics, IV inotropes or IV&#xD;
             vasodilators with discharge date within 30 days of screening or acute mechanical&#xD;
             support (e.g., intra-aortic balloon pump, endotracheal intubation, mechanical&#xD;
             ventilation, or any ventricular assist device) with discharge date within 90 days of&#xD;
             screening.&#xD;
&#xD;
          3. Symptomatic hypotension or systolic blood pressure (SBP) ≤ 90 millimeters of mercury&#xD;
             (mmHg) at screening.&#xD;
&#xD;
          4. Uncontrolled hypertension (HTN) (SBP &gt; 160 mmHg or diastolic blood pressure (BP) &gt; 100&#xD;
             mmHg) prior to screening.&#xD;
&#xD;
          5. Heart transplant, and/or Left Ventricular Assist Device (LVAD) prior to screening or&#xD;
             anticipated heart transplant or LVAD during the study.&#xD;
&#xD;
          6. Implantation of a cardiac resynchronization therapy device (CRT) within 3 months prior&#xD;
             screening or intent to implant a CRT within 3 months after screening.&#xD;
&#xD;
          7. Acute coronary syndrome, unstable angina, stroke, transient ischemic attack (TIA),&#xD;
             coronary revascularization, cardiac device implantation, cardiac valve repair, carotid&#xD;
             or other major surgery within 3 months of screening.&#xD;
&#xD;
          8. Coronary, valve or carotid artery disease likely to require surgical or percutaneous&#xD;
             intervention within the 3 months after screening.&#xD;
&#xD;
          9. Severe pulmonary disease with any of the following:&#xD;
&#xD;
               1. Requirement of continuous (home) oxygen or&#xD;
&#xD;
               2. Known diagnosis of severe chronic obstructive pulmonary disease (as defined by&#xD;
                  the American Thoracic Society/European Respiratory Society) or severe restrictive&#xD;
                  lung disease, in the opinion of the investigator.&#xD;
&#xD;
         10. Screening laboratory results as follows, or any other clinically significant&#xD;
             abnormalities in screening laboratory values that would render a participant&#xD;
             unsuitable for inclusion in the opinion of the investigator.&#xD;
&#xD;
               1. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) &gt; 2.0 × upper limit&#xD;
                  of normal (ULN).&#xD;
&#xD;
               2. Total bilirubin ≥ 1.5 × ULN (participants with total bilirubin ≥ 1.5 × ULN may be&#xD;
                  allowed on study if indirect bilirubin only is elevated, ALT/AST is not greater&#xD;
                  than the ULN, and known to have Gilbert's disease).&#xD;
&#xD;
               3. Platelets &lt; 100,000/millimeter^3 (mm^3).&#xD;
&#xD;
               4. Urine protein creatinine ratio (UPCR) ≥ 500 milligrams per gram (mg/g).&#xD;
&#xD;
               5. Hemoglobin A1c (HbA1c) &gt; 9.5% or uncontrolled diabetes per investigator&#xD;
                  judgement.&#xD;
&#xD;
               6. Estimated glomerular filtration rate (eGFR) &lt; 40 milliliters/minute /1.73 m^2&#xD;
                  (mL/min/1.73 meter^2) at screening.&#xD;
&#xD;
               7. Abnormal thyroid function tests with clinical significance per investigator&#xD;
                  judgement.&#xD;
&#xD;
               8. Serum potassium &gt; 4.7 millimoles per liter (mmol/L) at screening.&#xD;
&#xD;
         11. Requirement of treatment with both ACEi and ARBs.&#xD;
&#xD;
         12. Previous history of intolerance to ACEi or ARBs or history of hyperkalemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 942-2721</phone>
    <email>ionisNCT04836182study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research - Crystal River</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Generation of Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Heart Center</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Heart and Vascular Cardiology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newton Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>York Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewa Mirek-Bryniarska Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Kraków</city>
        <zip>30-082</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Wlodzimierz Kus</name>
      <address>
        <city>Lodz</city>
        <zip>94-255</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Chorob Serca w USK</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>AGT</keyword>
  <keyword>NT-proBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

